Geopolitical
MEDIUMTrigger: Chinese competition
Monitor: geopolitical
SMS Pharmaceuticals Ltd (Pharma - API & CRAMS) — fundamental analysis, earnings data, and key metrics. PE: 34.8. ROE: 14.3%. This stock is not currently in the Nifty 500 momentum outperformers list.
Earnings deceleration risks from management commentary
Trigger: Chinese competition
Monitor: geopolitical
Trigger: raw material volatility
Monitor: commodity
Key quotes from recent conference calls
“faces headwinds from raw material volatility and Chinese competition [Risk (geopolitical): MEDIUM]”
“faces headwinds from raw material volatility [Risk (commodity): MEDIUM]”
The above analysis is parsed from publicly available earnings call transcripts. This is educational research only — not investment advice. Last updated Apr 30, 2026.
Based on publicly available financial data. This is educational research, not investment advice.
SMS Pharmaceuticals Ltd's latest quarterly results (Mar 2026) show
SMS Pharmaceuticals Ltd's current PE ratio is 34.8x.
SMS Pharmaceuticals Ltd's price-to-book ratio is 4.5x.
SMS Pharmaceuticals Ltd's fundamental strength based on key financial ratios
SMS Pharmaceuticals Ltd has a debt-to-equity ratio of N/A.
SMS Pharmaceuticals Ltd's return ratios over recent years
SMS Pharmaceuticals Ltd's operating cash flow is positive (FY2026).
SMS Pharmaceuticals Ltd's current dividend yield is 0.11%.
SMS Pharmaceuticals Ltd's shareholding pattern (Mar 2026)
SMS Pharmaceuticals Ltd's promoter holding has remained stable recently.
SMS Pharmaceuticals Ltd is an established outperformer with 1 weeks of consecutive Nifty 500 outperformance.
SMS Pharmaceuticals Ltd has 2 key risks worth monitoring
In Sep 2025, SMS Pharmaceuticals Ltd's management highlighted
Based on quantitative research signals, here is why SMS Pharmaceuticals Ltd may be worth studying
SMS Pharmaceuticals Ltd investment thesis summary:
SMS Pharmaceuticals Ltd's forward outlook based on current data signals
The above FAQs are generated from publicly available earnings data and conference call transcripts. This is educational research only. Sector Alpha is not SEBI registered and does not provide investment advice.